News | 01 August 2026
SMS Pharma Q1 FY27 PAT rises 16% to Rs. 21.1 crore
Standalone revenue reaches Rs. 206.96 crore, while profit before tax climbs nearly 18% year-on-year
Standalone revenue reaches Rs. 206.96 crore, while profit before tax climbs nearly 18% year-on-year
Consolidated revenue from operations rises 13%, while profit before tax jumps 42% on strong operational performance
Consolidated income from operations rises to Rs. 46.63 crore, while profit more than triples sequentially on improved operational performance
Company evaluating legal options after pricing regulator seeks recovery related to Symbicort Turbuhaler for 2016–2025 period
EBITDA margin climbs to 36.6% and PAT rises 31.8% YoY, even as the company ramps up R&D spend and greenfield capacity across its API and CDMO businesses
Domestic and Africa businesses drive a strong quarter even as Middle East disruptions dent Asia sales; Equirus Securities retains REDUCE rating citing rising costs and stretched valuations
The company also reduced its net debt by Rs. 11.9 crore during the quarter, maintaining a Net Debt-to-EBITDA ratio of 1.52x despite increased working capital investments
Supported by focused therapy expansion, new product launches and improved field-force productivity, company also entered the Top 50 Indian pharmaceutical companies by market ranking
The acquisition of Aequitas Healthcare is expected to significantly strengthen Jagsonpal's specialty portfolio and provide immediate access to more than 1,000 hospitals across India
The move aimed at creating a focused API business under RPG Active Pharma comes with an initial investment of up to Rs. 243 crore
Ashland reported 6% growth in sales volumes year-over-year, with gains across its entire portfolio
Former Sai Life Sciences executive to lead chemical development and strengthen Syngene's R&D capabilities
Generic version of Merck's BRIDION targets a $1.6 billion US market, expands Glenmark's injectables portfolio
Leadership changes strengthen API business and global finance function
As the company's domestic branded formulations business grows 14%, GLP-1 brand Sundae emerges as market leader by prescriptions
Efficient conclusion to the Talc Litigation that eliminates expense associated with litigating remaining roughly 76,000 ovarian Talc claims
Regulated Markets business surges 42%, EBITDA rises 87% as company expands US portfolio and manufacturing capacity
Revenue from operations climbs to Rs. 653.2 crore as pharmaceutical major posts healthy profit growth in the June quarter
The company said it expects the approval to provide LYTENAVA with 12 years of Reference Product Exclusivity under the Biologics Price Competition and Innovation Act
Initiative aims to facilitate 2.5 lakh screenings through 8,500 camps; over 5,000 doctors support first phase of 1.5 lakh screenings
Subscribe To Our Newsletter & Stay Updated
